Cogentix Medical Inc  

(Public, NASDAQ:CGNT)   Watch this stock  
Find more results for NASDAQ:VSCI
1.02
-0.01 (-0.97%)
Real-time:   3:22PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.96 - 1.06
52 week 0.71 - 1.72
Open 1.05
Vol / Avg. 41,650.00/107,088.00
Mkt cap 26.73M
P/E     -
Div/yield     -
EPS -0.29
Shares 25.95M
Beta 0.99
Inst. own 36%
Jul 29, 2016
Cogentix Medical Inc Annual Shareholders Meeting (Estimated) - 2:30PM EDT - Add to calendar
May 24, 2016
Cogentix Medical Inc Annual Shareholders Meeting
May 5, 2016
Q1 2016 Cogentix Medical Inc Earnings Call - Webcast
May 5, 2016
Q1 2016 Cogentix Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -7.92% -
Operating margin -4.54% -
EBITD margin - -
Return on average assets -8.02% -
Return on average equity -23.45% -
Employees 178 -
CDP Score - -

Address

5420 Feltl Rd
MINNETONKA, MN 55343-7982
United States - Map
+1-952-4266140 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cogentix Medical, Inc., formerly Vision-Sciences, Inc., is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System, a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.

Officers and directors

Darin Hammers Interim Chief Executive Officer, Chief Operating Officer
Bio & Compensation  - Reuters
Brett A. Reynolds Chief Financial Officer, Senior Vice President, Principal Financial Officer, Principal Accounting Officer, Secretary
Age: 47
Bio & Compensation  - Reuters
Kenneth H. Paulus Director
Age: 56
Bio & Compensation  - Reuters
Cheryl Pegus M.D. Director
Age: 51
Bio & Compensation  - Reuters
Lewis C. Pell Director
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kevin H. Roche Director
Age: 63
Bio & Compensation  - Reuters
Howard I. Zauberman Director
Age: 62
Bio & Compensation  - Reuters